{"name": "Novagali Pharma",
 "permalink": "novagali-pharma",
 "crunchbase_url": "http://www.crunchbase.com/company/novagali-pharma",
 "homepage_url": "http://www.novagali.com/",
 "blog_url": "",
 "blog_feed_url": "",
 "twitter_username": "",
 "category_code": "biotech",
 "number_of_employees": null,
 "founded_year": null,
 "founded_month": null,
 "founded_day": null,
 "deadpooled_year": null,
 "deadpooled_month": null,
 "deadpooled_day": null,
 "deadpooled_url": null,
 "tag_list": "",
 "alias_list": "",
 "email_address": "contact@novagali.com",
 "phone_number": "+ 33 1 69 87 40 20",
 "description": "",
 "created_at": "Thu Sep 29 04:21:26 UTC 2011",
 "updated_at": "Thu Sep 29 04:24:13 UTC 2011",
 "overview": "\u003Cp\u003ENovagali Pharma S.A, an ophthalmic pharmaceutical company, develops products for various segments of the eye. Using its technology platforms Novasorb and Eyeject, the company develops a pipeline of products addressing ocular conditions, as well as orphan diseases. It offers Cationorm, an oil in water emulsion for the treatment of dry eye symptoms; and is developing Cyclokat (Cyclosporine A), a Phase III product candidate for treating moderate to severe dry eye; Catioprost, a Phase II product candidate for treating glaucoma; and Vekacia, a Phase III product candidate for treating vernal keratoconjunctivitis. Novagali Pharma is also developing Cortiject, a Phase I candidate for treating diabetic macular edema. The company was founded in 2000 and is based in Evry, France.\u003C/p\u003E",
 "image": null,
 "products":
  [],
 "relationships":
  [{"is_past": false,
    "title": "President \u0026 CEO",
    "person":
     {"first_name": "J\u00c3\u00a9r\u00c3\u00b4me",
      "last_name": "MARTINEZ",
      "permalink": "jrme-martinez",
      "image": null}},
   {"is_past": true,
    "title": "Board memeber",
    "person":
     {"first_name": "R\u00e9mi",
      "last_name": "Droller",
      "permalink": "rmi-droller",
      "image":
       {"available_sizes":
         [[[109,
            150],
           "assets/images/resized/0027/5900/275900v1-max-150x150.jpg"],
          [[183,
            250],
           "assets/images/resized/0027/5900/275900v1-max-250x250.jpg"],
          [[230,
            314],
           "assets/images/resized/0027/5900/275900v1-max-450x450.jpg"]],
        "attribution": ""}}}],
 "competitions":
  [],
 "providerships":
  [],
 "total_money_raised": "$0",
 "funding_rounds":
  [],
 "investments":
  [],
 "acquisition": null,
 "acquisitions":
  [],
 "offices":
  [{"description": "",
    "address1": "1 rue Pierre Fontaine",
    "address2": "Genavenir IV",
    "zip_code": "F-91058",
    "city": "Evry cedex",
    "state_code": null,
    "country_code": "FRA",
    "latitude": null,
    "longitude": null}],
 "milestones":
  [{"description": "Santen strikes $139M deal to snap up Novagali's eye treatments\r\n",
    "stoned_year": 2011,
    "stoned_month": 9,
    "stoned_day": 28,
    "source_url": "http://www.fiercebiotech.com/story/santen-strikes-139m-deal-snap-novagalis-eye-treatments/2011-09-28?utm_medium=rss\u0026utm_source=rss",
    "source_text": "",
    "source_description": "Santen strikes $139M deal to snap up Novagali's eye treatments",
    "stoneable_type": "Company",
    "stoned_value": null,
    "stoned_value_type": null,
    "stoned_acquirer": null,
    "stoneable":
     {"name": "Novagali Pharma",
      "permalink": "novagali-pharma"}}],
 "ipo": null,
 "video_embeds":
  [],
 "screenshots":
  [],
 "external_links":
  []}